Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Idera Makes Leadership Additions

This article was originally published in Scrip

Executive Summary

Idera Pharmaceuticals, Inc., has made several leadership additions: appointing Mark J. Cornfeld vice president and medical lead for oncology; Kirsten L. Gruis senior medical director for rare diseases; Tanya N. Lewis vice president of regulatory affairs and quality assurance; and John J. Kirby vice president of corporate accounting. Cornfeld recently held various oncology leadership roles at GlaxoSmithKline and prior to this he was at Johnson & Johnson and Hoffman-LA Roche. Most recently Gruis was director, clinical development at Alnylam Pharmaceuticals and before this she was neuromuscular clinical lead at Pfizer Inc. Lewis has been vice president of regulatory affairs and medical writing at Tesaro, Inc before which she held regulatory roles at Seaside Therapeutics, Vion Pharmaceutical, Millennium Pharmaceuticals and Genzyme Corporation. Finally, Kirby joins Idera from Endo Pharmaceuticals, where most recently he was assistant controller.

You may also be interested in...

Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?

How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.

Adherence Issues Add Weight To Digital Trials Push

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts